Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

摘要: Cachexia is characterized by severe weight loss, including adipose and muscle wasting, occurs in a large percentage of cancer patients. Insulin resistance contributes to dysregulated metabolism cachexia prior loss mice with colon-26 tumor-induced cachexia. Therefore, we hypothesized that the insulin sensitizer, rosiglitazone, would attenuate result improved outcomes for late-stage Male CD2F1 were inoculated adenocarcinoma cells or vehicle. Treatments included vehicle, rosiglitazone (10 mg/kg body weight/day) plus pair-feeding food intake vehicle-treated tumors. Rosiglitazone delayed onset 2 d over 16 duration this aggressive tumor model. This finding was associated, part, increased intake. In addition, mass, adipocyte cross-sectional area inflammation rosiglitazone. However, at time necropsy after inoculation had no effect on retention strength proteolysis We did not measure stamina endurance study. early-stage cachexia, normalized PDK4 PPAR-delta mRNA quadriceps rescued decrease insulin-stimulated glucose disappearance may delay decreasing markers metabolic change These changes predict modest improvement adipose, but